Department of Pharmacy Practice, Midwestern University Chicago College of Pharmacy, 555 31st Street, Downers Grove, IL 60515, USA; Department of Pharmacy, Northwestern Memorial Hospital, 251 E. Huron Street, Feinberg Pavilion, LC 700, Chicago, IL 60611, USA.
Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT, USA.
Int J Antimicrob Agents. 2017 Sep;50(3):487-490. doi: 10.1016/j.ijantimicag.2017.04.023. Epub 2017 Jun 28.
The quantitative impact of severity of illness on pharmacodynamic thresholds is poorly defined. We used a robust cefepime outcomes cohort and previously identified pharmacodynamic breakpoints of 68% [pharmacokinetic (PK) model 1] and 74% (PK model 2) to probe interactions and relationships with modified Acute Physiology and Chronic Health Evaluation (mAPACHE) II scores. When the time that serum concentration remains above the minimum inhibitory concentration during the dosing interval (fT) was optimised, mortality was improved between mAPACHE II scores of 9-23 and 9-22 in models 1 and 2, respectively. No significant interactions were identified. These results suggest that mAPACHE II scores of 9-22 may fall within a 'Goldilocks' window in which hospital survival is improved among patients achieving goal fT thresholds.
疾病严重程度对药效学阈值的定量影响尚未明确。我们使用了一个强大的头孢吡肟治疗结局队列,并利用先前确定的 68%(PK 模型 1)和 74%(PK 模型 2)的药效学折点来探讨与改良急性生理学和慢性健康评估(mAPACHE)II 评分的相互作用和关系。当优化血清浓度在给药间隔期间高于最低抑菌浓度的时间(fT)时,在模型 1 和模型 2 中,mAPACHE II 评分在 9-23 和 9-22 之间,死亡率分别得到改善。未发现显著的相互作用。这些结果表明,mAPACHE II 评分在 9-22 之间可能处于“黄金范围”,在此范围内,达到目标 fT 阈值的患者的住院生存率得到提高。